TABLE 6.

Top 10 co-cited references in UC research.

Rank	References	Co-citation	Publishing year
1	Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis	103	2012
2	Tofacitinib as induction and maintenance therapy for ulcerative colitis	99	2017
3	Vedolizumab as induction and maintenance therapy for ulcerative colitis	97	2013
4	Early mucosal healing with infliximab is associated with improved long-term clinical outcomes in ulcerative colitis	96	2011
5	Beyond endoscopic mucosal healing in UC: histological remission better predicts corticosteroid use and hospitalization over 6 years of follow-up	85	2016
6	Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis	84	2014
7	Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis	82	2014
8	Adalimumab for induction of clinical remission in moderate-to-severe active ulcerative colitis: results of a randomized controlled trial	76	2011
9	Colectomy rate comparison after treatment of ulcerative colitis with placebo or infliximab	61	2009
9	Ciclosporin vs. infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label, randomized controlled trial	61	2012
10	Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis	58	2014
10	Development and validation of the Nancy histological index for UC	58	2017

Note: Document co-citation occurs when two publications are co-cited (cited together) in subsequent publications, suggesting intellectual closeness between the two articles. The purpose of this analysis is to determine the time evolution of the most influential publications and the most pursued themes over time. Count refers to the total number of publications.